Trends in survival for metastatic soft-tissue sarcoma: A French Sarcoma Group (GSF) database analysis.

Abstract

10045 Background: Treatment of metastatic soft-tissue sarcoma (STS) has evolved over the last two decades with the improvement of supportive care,theincreased use of loco-regional treatments, the widespread use of additional lines of chemotherapy and the increasing participation of STS patients (pts) in investigational agents trials. The aim of this study is to evaluate the changes in overall survival (OS) of pts with metastatic STS. Methods: 1,024 consecutive pts with synchronous (SM) or metachronous metastatic (MM) STS diagnosed between 1987 and 2006 were included prospectively in the GSF database after central histological review. Four period of diagnosis of metastatic disease were defined: P1=1987-91: n=208, P2=1992-96: n= 287, P3=1997-2001: n=285, and P4 = 2002-2006: n=244). OS was estimated by the Kaplan-Meier method. Results: The proportion of pts with SM, the time to diagnosisof MM and theclinical characteristics (age, sex, histological subtype, grade, site of metastasis) were similar across the four periods. There was no significant difference in the median OS times from P1 through P2 (P1 = 12.3 months (m) 95% CI [9.9-14.7]; P2 = 11.4 m 95% CI [9-13.9]). However, significant improvements were seen in the later periods: P3 = 15 m 95% CI [11.8-18.2]; P4 = 18 m 95% CI [15.3-20.7] (log-rank test: P = 0.029). The 2-year OS rate has also increased all along the study period: P1= 28.1% 95% CI [22-34.5], P2 = 32% 95% CI [26.6-37.5], P3= 33.3% 95% CI [27.8-39], P4= 38.7%, 95% CI [32.3-45]. On multivariate analysis, period of diagnosis, age, histological subtype, time to metastatic relapse, FNCLCC grade and number of metastatic sites were independent prognostic factors for OS. Conclusions: Median OS of pts with metastatic STS has improved by 50% during the last 20 years. These data should be considered for the interpretation of the results of ongoing and future STS trials. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis, Pfizer, PharmaMar